Eficacia de anastrozol como endocrinoterapia neoadyuvante en pacientes postmenopáusicas con cáncer de mama, estadios II y III.

SPURI P; BONANSONE N; REAL N; RIZZO G; MAURE M; CIANI S; MONGE C; VALDEMORO P; GAMARRA-LUQUES, C; PERELLÓ S; CIOCCA L; GOMEZ-GUASH S; VILLALOBOS W

Revista Argentina de Mastología

Sociedad Argentina de Mastología

Lugar: Buenos Aires; Año: 2023 vol. 42 p. 30 - 54

0326-2219

The neoadjuvant therapy with aromatase inhibitors (AI) represents a novel therapeutics strategy in patients with ER+ and HER2- tumors. Recent studies demonstrated that treatments with AI have a similar efficacy than conventional chemotherapy, although its significantly reduced adverse effects. The goal of the present study was to evaluate the neoadjuvant treatment efficacy using the AI anastrozole. The Ki67 levels determination, tumoral responses, complete pathologic responses and percentage of conservative surgery treatments are considered as indicators of response to treatment. In 32 patients, the administration of anastrozole for 24 weeks was observed to determine a frank response evidenced by decrease in tumor size, decreasing the clinical stage in 56% and increasing the ratio of breast conservative surgeries in 77%. The PR (-), was identified as tumoral marker related to treatment poor response. Into the classical lobular histological variant, all the treated cases evidenced a significant tumor size reduction.